BR0307421A - Estimulação do cpt-1 como um freio para reduzir peso - Google Patents

Estimulação do cpt-1 como um freio para reduzir peso

Info

Publication number
BR0307421A
BR0307421A BR0307421-8A BR0307421A BR0307421A BR 0307421 A BR0307421 A BR 0307421A BR 0307421 A BR0307421 A BR 0307421A BR 0307421 A BR0307421 A BR 0307421A
Authority
BR
Brazil
Prior art keywords
cpt
agent
administered
fatty acid
amount sufficient
Prior art date
Application number
BR0307421-8A
Other languages
English (en)
Inventor
Jagan N Thupari
Leslie E Landree
Gabriele Ronnett
Francis P Kuhajda
Original Assignee
Johns Kophkins University Scho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Kophkins University Scho filed Critical Johns Kophkins University Scho
Publication of BR0307421A publication Critical patent/BR0307421A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pediatric Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"ESTIMULAçãO DO CPT-1 COMO UM FREIO PARA REDUZIR PESO".Esta invenção provê métodos e composições para indução da perda de peso e mantendo peso ótimo compreendendo a administração de uma agente que estimula a atividade da carnitina-palmitoil-transferase-1 (CPT-1) ao paciente em necessidade, incluindo pacientes humanos. Estes métodos não requerem a inibição da síntese de ácido graxo. Em particular, esta invenção provê métodos desenvolvimento de terapêuticas que seletivamente intensificam a oxidação de ácido graxo, aumenta a produção de energia, e reduz a adiposidade enquanto preserva a massa magra, através da estimulação farmacológica da atividade do CPT-1. Em uma maneira preferida, o agente é administrado em uma quantidade suficiente para aumentar a oxidação de ácido graxo. Em outra maneira preferida, o agente é administrado em uma quantidade suficiente para antagonizar a inibição do malonil-CoA do CPT-1. Em ainda outra maneira preferida, o agente é administrado em uma quantidade suficiente para aumentar o nível de malonil-CoA.
BR0307421-8A 2002-02-08 2003-02-10 Estimulação do cpt-1 como um freio para reduzir peso BR0307421A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35448002P 2002-02-08 2002-02-08
PCT/US2003/003839 WO2003066043A1 (en) 2002-02-08 2003-02-10 Stimulation of cpt-1 as a means to reduce weight

Publications (1)

Publication Number Publication Date
BR0307421A true BR0307421A (pt) 2004-12-28

Family

ID=27734382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307421-8A BR0307421A (pt) 2002-02-08 2003-02-10 Estimulação do cpt-1 como um freio para reduzir peso

Country Status (12)

Country Link
US (4) US20050143467A1 (pt)
EP (1) EP1471906A4 (pt)
JP (2) JP2005523270A (pt)
KR (1) KR20040082417A (pt)
CN (1) CN1313089C (pt)
AU (2) AU2003215111A1 (pt)
BR (1) BR0307421A (pt)
CA (1) CA2474884A1 (pt)
EA (1) EA007029B1 (pt)
IL (1) IL163312A (pt)
MX (1) MXPA04007556A (pt)
WO (1) WO2003066043A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
CA2767092C (en) * 2002-07-09 2013-10-15 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same and methods of use for same
EP1732572A4 (en) * 2004-03-18 2007-04-18 Fasgen Llc REGULATION OF FOOD BEHAVIOR BY MODIFICATION OF THE NEURONAL ENERGY BALANCE
CN101022792A (zh) * 2004-05-26 2007-08-22 法斯根有限责任公司 新化合物、包含该化合物的药物组合物及该化合物的应用方法
ATE466838T1 (de) * 2005-06-06 2010-05-15 Hoffmann La Roche Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
US20100168218A1 (en) * 2005-07-26 2010-07-01 Kuhajda Francis P Method of reducing food intake
EP1760147B1 (en) * 2005-08-29 2008-12-24 F. Hoffmann-La Roche Ag Crystal structures of carnitine palmitoyltransferase-2 (CPT-2) and uses thereof
ES2405259B1 (es) * 2011-11-25 2014-09-29 Centro De Investigación Biomédica En Red Fisiopatología De La Obesidad Y Nutrición (Ciberobn) Uso del enantiómero (+)-c75 para el tratamiento de la obesidad.
WO2013155528A2 (en) * 2012-04-13 2013-10-17 Fasgen, Inc. Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574639A (en) 1897-01-05 Gold-saving device
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5914326A (en) * 1997-08-08 1999-06-22 Ambi Inc. Method for promoting weight and fat loss
WO2000012080A1 (en) * 1998-09-01 2000-03-09 Amway Corporation Diet composition and method of weight management
ATE330598T1 (de) * 1999-11-12 2006-07-15 Univ Johns Hopkins Behandlung von krebs durch erhöhung des malonyl- coa-spiegels
KR20030016228A (ko) * 2000-02-16 2003-02-26 존스 홉킨스 유니버시티 스쿨 오브 메디슨 신경펩티드 y 농도의 감소에 의해 유도되는 체중 감량
WO2002079501A1 (en) * 2001-03-30 2002-10-10 Trustees Of Boston University Methods and reagents for identifying weight loss promoters and therapeutic uses therefor
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
US20040161803A1 (en) * 2002-04-01 2004-08-19 Corkey Barbara E. Methods and reagents for identifying weight loss promoters and therpeutic uses therefor
BRPI0312413A2 (pt) 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
CA2767092C (en) 2002-07-09 2013-10-15 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same and methods of use for same

Also Published As

Publication number Publication date
US20050106217A1 (en) 2005-05-19
MXPA04007556A (es) 2005-12-05
CN1313089C (zh) 2007-05-02
US20090124684A1 (en) 2009-05-14
IL163312A (en) 2011-12-29
US7459481B2 (en) 2008-12-02
EP1471906A1 (en) 2004-11-03
US20070087037A1 (en) 2007-04-19
KR20040082417A (ko) 2004-09-24
WO2003066043A1 (en) 2003-08-14
AU2008249144A1 (en) 2008-12-11
JP2010047594A (ja) 2010-03-04
EA200401052A1 (ru) 2005-02-24
CN1638758A (zh) 2005-07-13
AU2003215111A1 (en) 2003-09-02
JP2005523270A (ja) 2005-08-04
EP1471906A4 (en) 2006-02-01
EA007029B1 (ru) 2006-06-30
US20050143467A1 (en) 2005-06-30
CA2474884A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
BRPI0518398A2 (pt) Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
FI920026A0 (fi) Farmaceutisk komposition anvaendbar som avmagringsmedicin.
DE60221853D1 (de) Schuhinnensohle für fussrehabilitation
EA200701131A1 (ru) Гелеобразная препаративная форма капсаициноида и способы её применения
Liu et al. The effect of the modified eighth section of eight-section brocade on osteoporosis in postmenopausal women: a prospective randomized trial
Wilson et al. Effect of skeletal muscle fiber type on the pressor response evoked by static contraction in rabbits
BR0307421A (pt) Estimulação do cpt-1 como um freio para reduzir peso
CA2761458C (en) Fragrance composition having good sleep-inducing effect
JP2004532215A (ja) 睡眠時の自律的安定性に関するカンナビノイドの機能的役割
BR9911020A (pt) Novas composições farmacêuticas para tratamento e salvamento, e método para a sua preparação
JP2021526947A (ja) 美容、脳卒中、特発性顔面神経麻痺患者が顔の骨および筋肉を鍛えるための装置および使用方法
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Starnes et al. Synergistic effect of exercise and statins on femoral strength in rats
Yuan et al. Application and progress of blood flow restriction training in improving muscle mass and strength in the elderly
Jafari et al. Respiratory hypoalgesia? Breath-holding, but not respiratory phase modulates nociceptive flexion reflex and pain intensity
Liu et al. Overview of physical and pharmacological therapy in enhancing bone regeneration formation during distraction osteogenesis
Verburg et al. Muscle contractile properties during intermittent nontetanic stimulation in rat skeletal muscle
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
Sutherland et al. Pattern dependence in the stimulation-induced type transformation of rabbit fast skeletal muscle
BR0316025A (pt) Lenço para melhorar a saúde da pele, produto para melhorar a saúde da pele e método para aumento da concentração intracelular de ceramidas
DE502005001398D1 (de) Hautpflegeprodukt enthaltend Ursolsäure und Ginkgo-Extrakt
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
Kozlovskaya et al. The system of preventive measures in long space flights
RU2302256C1 (ru) Ароматическая композиция, нормализующая психоэмоциональное состояние (варианты)
HUP0002643A2 (hu) Szívrendellenességek kezelése és megelőzése SSRI-k alkalmazásával

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/195, 31/198, 31/205, 31/34, 31/381, 45/00; A61P 3/04, 43/00; G01N 33/15, 33/50

Ipc: A61K 31/195 (2011.01), A61K 31/198 (2011.01), A61K

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 9A ANUIDADE.